An observational, Post-Authorisation Safety Study (PASS) to describe the safety and effectiveness of tabelecleucel in patients with Epstein-Barr Virus positive (EBV+) Post-Transplant Lymphoproliferative Disease (PTLD) in a real-world setting in Europe: EBVOLVE study

Data sources

• Data source(s), other:
  The PASS database will contain complete study specific data for each patient enrolled in the study and will be based on the PASS eCRF that incorporates: (1) secondary use of data from the Health Care Professionnal portal database which will be automatically transferred, incorporated, and displayed in the PASS eCRF, and (2) primary data collection.
• Data sources (types):
  Non-interventional study

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Yes
• Check completeness:
  Yes
• Check stability:
  Yes
• Check logical consistency:
  Yes

Data characterisation

• Data characterisation conducted:
  No